Presentation is loading. Please wait.

Presentation is loading. Please wait.

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Similar presentations


Presentation on theme: "Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®"— Presentation transcript:

1 Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI® and BRAMITOB® (Tobramycin inhalation solutions)  John E. Moore, Yasunori Maeda, Colin E. Goldsmith, Jacqueline C. Rendall, J. Stuart Elborn  Journal of Cystic Fibrosis  Volume 9, Issue 3, Pages (May 2010) DOI: /j.jcf Copyright © 2010 Elsevier B.V. Terms and Conditions

2 Fig. 1 Determination of the coefficient of correlation (r2) calculated from the paired comparison of the in vitro antimicrobial susceptibilities of TOBI® versus BRAMITOB® performed in triplicate in 100 wildtype CF P. aeruginosa isolates. For ease of visualisation, graph ends at MIC<6μg/ml, but r2 and F-values have been calculated based on all 100 isolates tested. Journal of Cystic Fibrosis 2010 9, DOI: ( /j.jcf ) Copyright © 2010 Elsevier B.V. Terms and Conditions


Download ppt "Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®"

Similar presentations


Ads by Google